Broadcast Date: Tuesday, June 21, 2022
from 3:00 pm to 4:30 pm (ET)


Antitrust litigation in the life sciences sector has continued to grow and evolve, with a rapid mix of innovate theories and impactful court decisions over the past few years.  Pharmaceutical companies must constantly consider the changing landscape as they pursue their business strategies to avoid legal pitfalls, and attorneys must stay up-to-date on decisions and strategies that are shaping the next generation of litigation.

Listen as a panel of distinguished thought leaders organized by The Knowledge Group provide the audience with an in-depth discussion of the trends, developments, and critical issues surrounding pharmaceutical antitrust matters.  Our panel will provide the audience with insight on recent cases that are shaping the litigation battlefields of tomorrow, as well as thoughtful analysis of the key issues that separate the cases.  Using a phased approach, they will walk you through the background of these key cases, and separate out the implications for class certification, merits issue, and how expert testimony can be used most effectively.

Key topics that will be discussed in this course are:

  • Recent Pharmaceutical Antitrust Cases: An Overview
  • Critical Issues and Challenges in Class Certification
  • Considerations for Complex Merits Issues
  • Practical Guidance for Lifecycle Management
  • Implications for Expert Testimony
  • What Lies Ahead


Course Level:



Advance Preparation:

Print and review course materials


Method of Presentation:

On-demand Webcast (CLE)



General knowledge of antitrust laws


Course Code:



NY Category of CLE Credit:

Areas of Professional Practice


Total Credits:

1.5 CLE

Speaker Panel:

David Shotlander, Partner
Haug Partners LLP

David Shotlander is an antitrust Partner in the Washington, D.C. office of Haug Partners, focusing his practice on antitrust litigation, government investigations and counseling. Mr. Shotlander has a strong background in industrial economics and has provided antitrust and litigation services to corporate clients for over a decade – a mix of skill and experience that enables him to pointedly and successfully address the questions and problems faced by his clients. Mr. Shotlander has represented branded and generic pharmaceutical companies on matters involving critical and emerging antitrust issues, including “reverse payment” litigation. He has also represented parties in merger and civil non-merger investigations before the Federal Trade Commission, Department of Justice and state attorney generals, as well as foreign competition authorities.

Pavel Darling, Vice President
Analysis Group, Inc.

Pavel Darling, a Vice President in Analysis Group’s Boston office, provides consulting and expert testimony support in complex litigation matters. He has performed quantitative analyses to address litigation, strategy, and policy questions, primarily in the health care industry, and has extensive experience with a range of sophisticated economic modeling tools and techniques. Mr. Darling’s healthcare work frequently deals with antitrust issues including pharmaceutical reverse payment settlements, intellectual property and patent infringement, and competition, and covers all stages of litigation including class certification, liability, and damages assessments. Mr. Darling received his M.B.A. at the MIT Sloan School of Management.

Tram Nguyen, PhD, Principal Consultant
Edgeworth Economics

Dr. Tram Nguyen specializes in quantitative economic analysis and modeling within the context of labor and employment discrimination matters, industrial organization, and firm management. She has extensive experience analyzing large and varied datasets, as well as expertise in machine learning and statistical tools.

Dr. Nguyen has provided support to clients on issues related to the economics of class certification for both direct and indirect purchaser classes and applying rigorous econometric analyses in estimating antitrust damages in dozens of matters. Her casework spans a broad range of industries, including agricultural products, railroads, chemicals, pharmaceuticals, and consumer products. Across these fields, Dr. Nguyen has extensive experience in leading teams of consultants to conduct empirical analysis of economic issues and present analytical insights in expert reports.

Dr. Nguyen earned her PhD and MA in economics from Stanford University.


David Shotlander, Partner

Haug Partners LLP

  • Discussion of relevant pharma antitrust cases and theories

Pavel Darling, Vice President

Analysis Group, Inc.

  • Discussion of merits and Rule 702 issues in those cases

Tram Nguyen, PhD, Principal Consultant

Edgeworth Economics

  • Discussion of class certification issues in those cases

Date & Time:

Tuesday, June 21, 2022

3:00 pm to 4:30 pm (ET)

Who Should Attend:

  • Antitrust Lawyers & Consultants
  • Healthcare Law Attorneys
  • M&A Lawyers and Consultants
  • Corporate Counsel
  • General Counsel
  • Executives from Healthcare and Life Sciences Industry


David ShotlanderPartner
Haug Partners LLP
Pavel DarlingVice President
Analysis Group, Inc.
Tram Nguyen, PhDPrincipal Consultant
Edgeworth Economics



View Details


View Details


View Details

Join Over 150,000 Professionals Empowering Their Careers

Learn anywhere from over 1900+ live and recorded CLE, CPE & Technology Webcasts.